Sangamo Announces Updated Phase 1/2 STAAR Study Data in Fabry Disease Showing Sustained Benefit, Improvements in Kidney Function and a Favorable Safety Profile

Click here to view

Presentation

Poster: Isaralgagene Civaparvovec (ST-920) Gene Therapy in Adults with Fabry Disease: Updated Results from an Ongoing Phase 1/2 Study (STAAR)

Download PDF